Lili Arbely-Elbaz

Sr. Director Of Office Operetions & Communications at Vectorious Medical Technologies

Lili Arbely-Elbaz has a diverse work experience spanning different industries. Lili is currently the Director of Office Operations at Vectorious Medical Technologies, a position they have held since November 2022. Prior to this role, Lili was the Office Operations Manager at the same company from June 2021 to November 2022.

Before joining Vectorious Medical Technologies, Lili worked at Israel Seminar, where they held multiple roles from 2014 to 2021. Lili served as the Corporate Clients & Events Manager from 2017 to 2021, the VIP Client Success Manager from 2015 to 2017, and the Office Manager from 2014 to 2015.

In 2013, Lili founded their own business called LILI's, where they operated as the Owner & Designer. Lili'sentrepreneurial experience lasted until 2014.

Prior to starting their own business, Lili worked at Beit Berl College as the PA to the College President from 2010 to 2013. Lili also had a role at Dialogue - Organizational Consulting, Research and Training Ltd. as a Project Operations Manager at a Research Institute from 2009 to 2010.

Lili Arbely-Elbaz obtained a Master of Business Administration (MBA) degree with a specialization in Business & Managerial Psychology from The College of Management Academic Studies from 2009 to 2011. Prior to that, they completed their Bachelor's degree in Education, Sociology, and Anthropology from The Hebrew University of Jerusalem between 2005 and 2008.

Links


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Vectorious Medical Technologies

1 followers

Vectorious Medical Technologies developed the V-LAP, the worlds first in-heart microcomputer which enables optimal treatment for heart failure patients, increasing their quality of life and life expectancy.The V-LAP sensory implant is the first digital, wireless, battery-less device that is able to communicate from deep within the body. Itmonitors the heart’s left atrium pressure (LAP) which has been proven to be the earliest, most accurate and effective predictor for heart failure deterioration.Vectorious is actively conducting clinical studies in Europe (Italy, Germany, UK and Israel) for the purpose of obtaining a CE mark. It is expected to launch a clinical study in the US in 2020.


Headquarters

Tel Aviv, Israel

Employees

11-50

Links